| Objective:Neoadjuvant chemotherapy has become an important part of the standardized treatment of breast cancer. The clinical efficacy of neoadjuvant chemotherapy is affected by many factors. Reaction and prognosis on different patients also present significantly. The rate of pathological complete response(p CR) patients achieve after neoadjuvant chemotherapy is not consistent either. The purpose of this paper is to explore the influence factors of neoadjuvant chemotherapy, in order to provide evidence for individual and accurate treatment of breast cancer, so as to improve the curative effect and DFS/OS of patients. Methods:The study retrospectively evaluated 590 patients with primary breast cancer treated with neoadjuvant chemotherapy,whose clinical features, situation of tumor and pathological response to chemotherapy were recorded, and the effects on the efficacy of neoadjuvant chemotherapy of the relevant biological factors(ER, PR, HER-2, Ki-67 and molecular typing) were evaluated.Influence of the factors and the pathological response on the prognosis were analyzed according to the follow-ups. Results:Er negative patients are more likely to achieve PCR, which has statistical significance(p = 0.001). The same result is got on Pr negative patients(p< 0.001). Patients whose Ki-67≥14% are easier to achieve PCR than those whose Ki-67<14%(p < 0.05). Her-2 and molecular classification have nothing to do with the PCR rate in this study(p>0.05). ER positive patients and PR positive patients have better DFS and OS than ER negative patients and PR negative patients respectively(Both p< 0.05).However, there are no results with statistical significance show that PCR, HER-2, Ki-67 molecular typing have impacts on patient’ s DFS or OS(p> 0.05). Conclusion:the patients with ER negative, PR negative, or Ki-67≥14% are more likely to achieve PCR; ER and PR positive patients have better prognosis while the prognosis of patients with triple negative phenotype is pessimistic。... |
PDF Full Text Request